This price target is based on 0 analysts offering 12 month price targets for Origo Acquisition in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.
The current consensus among 0 contributing investment analysts is to n/a stock in Origo Acquisition. This N/A consensus rating has held steady for over two years.
Origo Acquisition Corporation, formerly CB Pharma Acquisition Corp., is a shell company. The Company is a blank check company formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities. The Company focuses on identifying a business to a particular industry or geographic region of the world. The Company is not engaged in any business operations. As of November 30, 2016, the Company had not generated any revenues.
Read More